A Randomized Phase 3 Study Of Sitravatinib In Combination With Nivolumab Versus Docetaxel In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On Or After Platinum-Based Chemotherapy In Combination With Checkpoint Inhibitor Therapy